New Two-Drug attack tested for tough childhood cancers
NCT ID NCT04751383
Summary
This early-phase study tested the safety and best dose of two antibody drugs, magrolimab and dinutuximab, given together to children and young adults whose neuroblastoma or osteosarcoma had come back or stopped responding to other treatments. The main goal was to see if the combination was safe and tolerable, and to find the right dose for future studies. Researchers also wanted to learn if the drugs could help shrink or stabilize tumors, and if they could be safely given after surgery to remove lung tumors in some osteosarcoma patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030, United States
-
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4, Canada
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
UCSF Medical Center-Mission Bay
San Francisco, California, 94158, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.